PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: tebu-bio

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

tebu-bio Named EpiCypher’s Exclusive European Distributor - tebu-bio is pleased to announce their agreement with EpiCypher™ to distribute their innovative product range throughout Europe - EpiCypher.com / tebu-bio.com
tebu-bio Named EpiCypher’s Exclusive European Distributor

 

NewswireToday - /newswire/ - Le Perray en Yvelines, Yvelines, France, 2014/01/30 - tebu-bio is pleased to announce their agreement with EpiCypher™ to distribute their innovative product range throughout Europe - EpiCypher.com / tebu-bio.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

tebu-bio (Le Perray, France) has signed an agreement with EpiCypher to bring European researchers access to EpiCypher’s product range, through their network of local offices in 9 countries.

EpiCypher, Inc (The Woodlands, TX, USA) develops and manufacturers novel tools for epigenetics and chromatin biology research, based on the expertise and unique insight of their industry-leading scientific team, who are renowned, experienced chromatin researchers.

Dr. Ali El Bayâ (Sales Manager Proteins & Protein based Products & Services) says "Epicypher's portfolio will perfectly complement tebu-bio's offer in the emerging field of Epigenetics. On one hand we will explore a new market with Epicypher's Histone Peptide Arrays: hundreds of highly purified histone derived peptides - unmodified and modified and spotted to the array - allowing in-depth interaction studies. On the other hand, Epicypher's native and recombinant nucleosome preparations and epigenetic enzymes will enlarge our offer for screening activities especially in the Drug Discovery environment."

“Our partnership with tebu-bio supports our continued commitment to our customers’ success” stated Jim Bone, President of EpiCypher. “During in-person discussions in Europe with tebu-bio, the opportunity to realize our mutual success became clear. As epigenetics gains importance in the global research field, this partnership will increase our presence in the global market to meet demand and further aid the realization of EpiCypher’s business strategy.”

About tebu-bio

tebu-bio (tebu-bio.com) is an expert in the supply & distribution of Life Sciences Lab Services & Reagents throughout Europe. Their own European based laboratories also provide R&D contract services. tebu-bio's online catalogue offers Life Science Researchers access to the most innovative range of over 650 000 references online.

About EpiCypher

EpiCypher (epicypher.com) is a leading epigenetics products and services company that provides research support to leading discovery groups in industry and academia. EpiCypher’s patented EpiGold™ Histone Peptide Array is the most advanced histone array currently available. EpiCypher also sells nucleosomes, recombinant histone binding proteins, peptides and antibodies, as well as peptide synthesis and peptide array screening services.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: tebu-bio

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


tebu-bio Named EpiCypher’s Exclusive European Distributor

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Sara Pierre - tebu-bio.com 
+33(0)1 30 46 39 00 sara.pierre[.]tebu-bio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any tebu-bio securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From tebu-bio / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Intrinsic Executive Search Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)